The SHL Perspective

Empowering Innovation

SHL's Molly® is an autoinjector designed to address various fill volumes of complex biologics. Built upon a preconfigured technology, Molly® aims to support shortened development timelines for pharmaceutical companies.

Feb 5-6 Paris, France Booth C64

Learn more at 2020 Pharmapack Europe

Molly® 2.25 is a large volume variation of the Molly® autoinjector, enabling it to accommodate the high volume requirement of complex biologics. With an upgrade in industrial design that is optimized for production, the new Molly® is designed to meet the evolving requirements of future autoinjectors such as scalable manufacturing.

The Molly® autoinjector supports fill volumes in the 1-2.25 mL range, enabling it to accommodate various volume requirements of complex biologics. Molly® is easy-to-use with its two-step operation, and is designed with a flange-shaped cap to prevent unwanted rolling.

Molly® 2.25

Molly® is an incredibly intuitive and easy-to-use autoinjector built with a preconfigured technology developed to minimize customer investments and speed up development timelines.

Bigger Volume

Close

Built for higher volume injections, Molly® 2.25 supports the trends for injection volumes in the 1-2.25mL range. This allows new drugs to be delivered in autoinjector and launched products to be dosed less frequently.

Better Grip

Close

Deepened ridges on Molly®’s cap enhances grip. Its flange-shaped top facilitates cap removal, and its rectangular contour prevents unwanted rolling to ance the device’s safety.

Easier Handling

Close

As a preconfigured offering, Molly® 2.25 is designed to be easily understood and accepted by a variety of patient groups. Having inherited the classic Molly®’s 2-step process, Molly® 2.25 is as compact, intuitive and easy to use.

Faster Timelines

Close

SHL’s final assembly, labeling and packaging services were established to create added value for our partners following the successful design and development of their device, resulting in a fully integrated service from device design to commercialization.

Preconfigured Technology

Close

A high-volume variation of SHL's classic Molly® autoinjector, Molly® 2.25 is a preconfigured device that can also support various levels of customization to meet client specifications. 

Preconfigured Technology

A high-volume variation of SHL's classic Molly® autoinjector, Molly® 2.25 is a preconfigured device that can also

support various levels of customization

to meet client specifications. 

Easier Handling

As a preconfigured offering, Molly® 2.25 is designed to be easily understood and accepted by a variety of patient groups. Having inherited the classic Molly®’s 2-step process, Molly® 2.25 is as compact, intuitive and easy to use.

Refined Design

Deepened ridges on Molly®’s cap enhances grip. Its flange-shaped top facilitates cap removal, and its rectangular contour prevents unwanted rolling to enhance the device’s safety.

Bigger Volume

Built for higher volume injections, Molly® 2.25 supports the trends for injection volumes in the 1-2.25mL range. This allows new drugs to be delivered in autoinjector and launched products to be dosed less frequently.

Faster Timelines

SHL’s final assembly, labeling and packaging services were established to create added value for our partners following the successful design and development of their device, resulting in a fully integrated service from device design to commercialization.

Molly® 2.25 is a large volume variation of the Molly® autoinjector, enabling it to accommodate the high volume requirement of complex biologics. With an upgrade in industrial design that is optimized for production, the new Molly® is designed to meet the evolving requirements of future autoinjectors such as scalable manufacturing.

The Molly® autoinjector supports fill volumes in the 1-2.25 mL range, enabling it to accommodate various volume requirements of complex biologics. Molly® is easy-to-use with its two-step operation, and is designed with a flange-shaped cap to prevent unwanted rolling.

Go to article: Home | An (in)active pill problemGo to article: EditorialGo to article: SHL Group Company InsightGo to article: Scandinavian HealthGo to article: ContentsGo to article: NSFGo to article: NewsGo to article: AlmacGo to article: Covid-19 executive briefing by GlobalDataGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Digital biomarkers are emerging as important predictive tools to support the gloGo to article: Accurate Biometrics Company Insight Go to article: Accurate BiometricsGo to article: Almost 70 potential Covid-19 drug and experimental compound candidates identifiedGo to article: Datwyler Company Insight Go to article: DatwylerGo to article: Risk assessment of Covid-19 on patients suffering from IBDGo to article: Zenatek Go to article: The pharma industry briefingGo to article: FargoGo to article: Another bump in the road for mumps treatmentGo to article: Last TechnologyGo to article: From Covid-19 to SARS: what becomes of the whistleblowers?Go to article: ButterworthGo to article: Peptomyc: the quest for a ‘universal’ cancer treatmentGo to article: Q&A: is pharma ready to address the health effects of climate change?Go to article: Modality SolutionsGo to article: Not-so-inactive ingredients: a sore spot for patients?Go to article: Beyond M&As: will 2020 be the year of the spin-off? Go to article: VEGA Company Insight Go to article: VEGA AustraliaGo to article: Q&A with Genocea: improving cancer treatment with precise, personalised targetsGo to article: MimotopesGo to article: Pharma Playbook: an inside look at Signals Analytics vast therapeutic database Go to article: ILC Dover Go to article: Deals in brief powered by GlobalDataGo to article: The key list powered by GlobalDataGo to article: Global markets and indices powered by GlobalDataGo to article: Macro-economic indicators (1 of 2) powered by GlobalDataGo to article: Macro-economic indicators (2 of 2) powered by GlobalDataGo to article: EventsGo to article: Next issue